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Vitamin D Receptor Expression in Dogs
J.A. Cartwright , A.G. Gow, E. Milne, D. Drummond, S. Smith, I. Handel, and R.J. Mellanby
Background: There is growing evidence linking low blood vitamin D concentration to numerous diseases in people and in dogs. Vitamin
D influences cellular function by signaling through the vitamin D receptor (VDR). Little is known about which non-skeletal tissues
express the VDR or how inflammation influences its expression in the dog.
Objectives: To define which non-skeletal canine tissues express the VDR and to investigate expression in inflamed small intestine.
Animals: Thirteen non-skeletal tissues were collected prospectively from 6 control dogs. Thirty-five dogs diagnosed with a chronic
enteropathy (CE) and 24 control dogs were prospectively enrolled and duodenal biopsies were evaluated for VDR expression.
Methods: Prospective; blinded assessment of canine intestinal VDR. Dogs with CE were included once other identifiable causes of
intestinal disease were excluded. Age matched controls were included with no intestinal clinical signs. VDR expression was assessed
immunohistochemically in all samples, using a Rat IgG VDR monoclonal antibody. Quantitative real-time polymerase chain reaction
(qPCR) was also used for duodenal biopsies.
Results: VDR expression as assessed by immunohistochemistry (IHC) was highest in the kidney, duodenum, skin, ileum and spleen, and
weak in the colon, heart, lymph node, liver, lung, and ovary. Gastric and testicular tissue did not express the VDR. There was no
statistical difference in duodenal VDR expression between the 24 healthy dogs and 34 dogs with CE when quantified by either qPCR
(P5 0.87) or IHC (P5 0.099).
Conclusions and Clinical Importance: The lack of down regulation of VDR expression in inflamed intestine contrasts with previous
studies in humans. Our findings support future studies to investigate whether vitamin D and its analogues can be used to modulate
intestinal inflammation in the dog.
Key words: Immunohistochemistry; Inflammatory bowel disease; Chronic enteropathy; Tight junctions.
V itamin D exerts its metabolic effects largely throughsignaling via the vitamin D receptor (VDR). Numerous
cell types express the VDR,1–3 a ligand activated transcrip-
tion factor, which is specific for and activated by binding 1,
25 dihydroxyvitamin D (1,25(OH)2D) and other vitamin D
metabolites. The cytoplasmic VDR then translocates to the
nucleus before heterodimerization with a retinoid X receptor
(RXR), after which the heterodimer binds to vitamin D
response elements. Finally, this binding results in recruit-
ment of various other nuclear proteins into a transcriptional
complex.4 This complex initiates and regulates the rate
of transcription of target genes by Ribonucleic acid
(RNA)-polymerase II.5 There are also several recognized
non-genomic actions of 1,25(OH)2D that are reported to be
facilitated by a different receptor,6 such as elevation of
cyclic guanosine monophosphate levels, activation of pro-
tein kinase C and increases in intracellular calcium levels.7
The binding of 1,25(OH)2D to the VDR can influence a
wide range of biological effects including cellular differen-
tiation, proliferation, and phenotypic changes.8,9 While the
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traditional roles of vitamin D have focused on its role in the
maintenance of skeletal health, the non-skeletal roles of
vitamin D have been intensively investigated over the last
30 years since the discovery that VDR was expressed by a
wide range of cell types. For example, many studies have
found an association between low serum concentrations of
25 hydroxyvitamin D (25(OH)D) and the development
and progression of various diseases in humans.10–12 These
include hypertension, diabetes, cancer, cardiovascular dis-
eases, autoimmune conditions, and infectious diseases, as
well as Crohn’s disease and ulcerative colitis,13,14 which are
both forms of inflammatory bowel disease (IBD).
The non-skeletal effects of vitamin D have only recently
been investigated in companion animals.15 Serum 25(OH)D
concentrations are lower in dogs with several chronic and
inflammatory diseases including spirocercosis,16 congestive
heart failure,17 renal disease,18 cancer,19 and dogs with a
chronic enteropathy (CE) and a protein losing enteropathy
(PLE).20–22 Despite the associations between vitamin D
status and numerous health outcomes in dogs, knowledge
about the non-skeletal effects of vitamin D remain poorly
explored in companion animals. Specifically, it remains
unclear which canine cell types express VDR and which
factors influence the expression of VDR. The aim of this
study was therefore to establish which non-skeletal tissues
express the VDR in dogs. We also aimed to investigate how
the expression of VDR changes in response to inflamma-
tion, using the canine duodenum as our study organ.
Method
Healthy Control Dog Population and Sample
Procurement
This study was approved by the University of Edinburgh Veterinary
Ethical Review Committee. Client consent was obtained for any clinical
material to be stored for future research or teaching purposes. Client
consent was also obtained for post euthanasia body donation when
applicable. Material for non-skeletal tissue expression of the VDR was
collected from 6 healthy dogs that were euthanized for non-health
related reasons. Thirteen non-skeletal tissues were collected from these
6 dogs; stomach, duodenum, ileum, colon, skin, kidney, spleen, liver,
mesenteric lymph node, heart, lung, and either ovary or testicle. All
samples from cadavers were collected within 30 minutes of euthanasia
to reduce the impact of autolysis. These samples were formalin fixed
and paraffin wax-embedded blocks were made using standard methods.
Immunohistochemistry
Four micron thick sections were cut and dried overnight at 378C on
Superfrost Ultra Plus slides,a and then at 608C for 25 minutes. After rehy-
dration with xylene and absolute ethanol the slides were rinsed with tris
buffered saline tween (TBST). Antigen retrieval was performed by
immersion in 0.01 M citrate acid, pH 6.0, or high pH bufferb (H-3300) at
1108C for 5 minutes (12 minutes total heat time). Slides were then cooled
for 5 minutes in running water. This was followed by rising in TBST.
Sections were incubated overnight at 48C with and without the primary
antibody (Table 1), and negative controls were made with an isotype con-
trol primary antibody (Table 1). Validation and evaluation of the optimal
concentration of each primary antibody was performed using serial anti-
body dilutions on the respective positive controls. Following incubation
with the primary antibody, endogenous peroxidases were blocked with
Dako REAL blocking solution (Agilent S2023)h for 10 minutes. The fol-
lowing secondary reagents and times were used: ImmPRESS anti rat
HRP mouse (MP-7444),b 15 minutes at room temperature, Envision anti
rabbit HRP (Agilent K4011)h or Envision anti mouse HRP (Agilent
K4007),h 40 minutes at room temperature depending on the primary anti-
body. After each incubation step, the sections were rinsed in TBST 3
times. Visualization was performed using DAB and Chromogen (Agilent
K3468)h for 10 minutes. The sections were counterstained with Harris
hematoxylin for 20 seconds, dehydrated and mounted using ClearVue
mountant.a Immunohistochemistry (IHC) for each antibody was per-
formed in batches of between 15 and 20 and a known positive tissue sec-
tion was incorporated into each staining run.
Chronic Enteropathy and Control Dog Population and
Sample Procurement
For the second aspect of the study, a comparison of dogs with CE and
control dogs, 2 populations were enrolled for assessment of duodenum,
as this was previously shown to express VDR.23 Control dogs for this
aspect of the study, were prospectively enrolled between 2013 and 2016
if they were being euthanized for non-gastrointestinal related reasons and
owners had given consent for body donation for research and teaching.
Inclusion criteria were as follows: no recent history of gastrointestinal
clinical signs, a negative fecal parasite analysis, and no recent medica-
tions. Full thickness samples from the duodenum were collected for his-
tology (formalin fixed) and endoscopic biopsy forceps were used to
collect samples from the duodenum for gene expression (RNALater).i
Client owned dogs with CE were enrolled prospectively over the same
period. For inclusion into the study dogs were required to have clinical
signs for at least 4 weeks, with all other causes of intestinal inflammation
excluded through standard examinations (hematology, biochemistry,
fecal analysis, abdominal ultrasound, endoscopy, and histology). For
each dog, details were also recorded to determine the canine inflamma-
tory bowel disease activity index (CIBDAI) score.24 Dogs were excluded
if they had been treated with glucocorticoids within 4 weeks of the proce-
dure. Gastrointestinal endoscopy was performed as standard and biopsy
samples were fixed in formalin and submitted for histopathological
assessment for diagnostic purposes. At the time of endoscopy, a biopsy
sample was also stored in RNALater.i These samples were agitated at
48C for up to 24 hours and then stored at 2808C until batch RNA extrac-
tion. Histopathology of all samples, control, and affected, was reviewed
by a single pathologist. Classification and scoring were performed based
on criteria previously published by the World Small Animal Veterinary
Association (WSAVA).25,26 This score consisted of a standard
Table 1. The primary antibodies and isotype controls used in this study.
Antibody Antibody Name Antibody Type Dilution
VDR Purified Rat IgG2b (9A7)c Monoclonal Rat 1:8000
VDR Isotype Purified Rat IgG2b Isotype Control (RTK4530)d Isotype Control 1:100
ECAD Purified Mouse Anti-E-Cadherine Monoclonal Mouse 1:4000
ECAD Isotype Purified Mouse IgG2a j Isotype Controlf Isotype Control 1:100
CLD2 Rabbit anti-Claudin-2g Polyclonal Mouse 1:2000
CLD2 Isotype Rabbit IgG Isotype Controlh Isotype Control 1:100
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assessment of 4 types of infiltrating leukocytes (intraepithelial lympho-
cytes, lamina propria lymphocytes, neutrophils, and eosinophils) and 5
morphological features (crypt distention, lacteal dilatation, mucosal fibro-
sis, villous stunting, and epithelial injury), all scored from 0 to 3. This
numerical score was cumulated and a total score allocated to each dog,
alongside a categorical morphological diagnosis (normal, mild, moderate,
and marked inflammation).
Quantification of Immunoreactive Cells
All sections were analyzed by the same clinical pathologist (EM),
who was blinded to case details. Quantification of VDR immunolabel-
ing was performed by a semi-quantitive method similar to previously
described.27
Evaluating the entire section, the overall stain intensity was scored
from 0 to 3, with 05 no stain/weak, 15moderate, 25 strong, and
35 very strong. The percentage of cells stained was also then evaluated
with 05 none to< 5%, 1 5< 25% of cells, 25 25–50% of cells,
35 51–75% of cells, 45>75% of cells stained. The total score per
sample was then calculated by intensity 3 percentage of cells, giving a
maximum range of the overall score (OS) of 0–12.
Duodenal samples from dogs with CE and control dogs were also
analyzed by IHC for 2 tight junction elements claudin 2 (CLD2) and E-
Cadherin (ECAD), as outlined in Table 1, which have been reported to
change with inflammation.28,29
The IHC for each antibody was scored according to the protocol
above. To ensure consistency, example images of each intensity score
for each antibody were used as a guide throughout the scoring process
and all slides were scored twice on different days. To also factor for
sample depth, the intestinal samples were allocated an additional sepa-
rate score for the villous tips, mid-villous region, and crypts. For forcep
biopsy samples, all biopsies on the sample slide were examined and
scores assigned for the slide as a whole. For the whole tissue samples
from healthy dogs, each tissue was scored for the tissue as a whole and
where staining was present in a particular cell type, nuclear, and cyto-
plasmic staining were recorded as present or absent.
Total Ribonucleic Acid Extraction and Reverse
Transcription
Total RNA for quantitative real-time polymerase chain reaction
(qPCR) analysis was isolated from the duodenal tissue by first homoge-
nizing the tissue with TRIzol.j A single biopsy was added with TRIzol
to a lyzing matrix D tubei and agitated at 4 m/s for 20 seconds with a
Precellys 24.j The mixture was incubated for 3 minutes with 1-Bromo-
3-chloropropane,k followed by centrifugation to elute the RNA. The
RNA from the homogenate was then extracted with a QIAGEN RNeasy
mini kitl per the manufacturer’s protocols. RNA concentrations from all
samples were measured on the NanoDrop ND-1000.m RNA purity was
assessed with the (A260/A280) value from the NanoDrop and by an
Agilent Tapestation 2100.n Synthesis of complementary deoxyribonu-
cleic acid (cDNA) was performed using the QIAGEN Omniscript
Reverse Transcription kitl per the manufacturer’s protocols. Briefly, a
master mix of deoxynucleotide (dNTP), RNase inhibitor, Omniscript
Reverse Transcriptase, RNAse-free water, a buffer solution and Oligo-
dT primero was added to each 1,000 lg of template RNA. These solu-
tions were then incubated at 378C. The product cDNA was stored at
2808C until qPCR reactions were performed in batches.
Quantitative Real-Time Polymerase Chain Reaction
Real-time qPCR experiments were performed in a Roche Light
Cycler 480p with a 12 mL reaction volume containing 4.5 mL cDNA,
1.25 mL primers, and 6.25 mL SYBR Green qPCR Master Mix. Reac-
tions were also performed without reverse transcriptase and without
template, using distilled deionized H2O to maintain volume to monitor
for contamination. A standard cycling program was used. Samples were
run at 508C for 2 minutes, 958C for 2 minutes, and then 40 cycles of
958C for 15 seconds followed by 608C for 30 seconds.
Primers for the VDR, 25-hydroxyvitamin D3 1-alpha-hydroxylase
(CYP27B1), ECAD, and CLD2 (Table 2) were designed by the Roche
primer design software based on canine sequences from the Ensembl
database as previously described,30 so that the predicted amplicon
would span exon-exon boundaries. The primers were assessed by Basic
Local Alignment Search Tool analysis (National Center for Biotechnol-
ogy Information). Sequences were tested with nucleic acid folding soft-
ware (OligoAnalyser 3.1) in concordance with MIQE guidelines.31
Primer sequences used for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), actin beta (ACTB), and Succinate dehydrogenase complex
subunit A (SDHA) were previously described (Table 2).32,33
Specificity of the products was verified for each target and refer-
enced with gel electrophoresis showing a single product of the desired
length. In addition, a melting curve analysis was performed for each
reference and target.
Multiple reference genes were selected in line with available guide-
lines.34 Reference genes (Table 2) were selected based on previous evi-
dence of high expression within the canine duodenum.33 Analysis of the
reference genes’ relative expression levels by the relative expression soft-
ware tool (REST) (M. Pfaffl [Technical University Munich] and QIAGEN
http://www.gene-quantification.de/rest-2009.html) identified no significant
Table 2. Reference and target gene primer sequences and reaction efficiency.
Reference or Target Gene
Forward Primer (5030)
Reverse Primer (50-30) Product Length (bp) Tm (8C) Reaction Efficiency R2
Reference ACTB CCAGCAAGGATGAAGATCAAG 100 57.9 110 0.98
TCTGCTGGAAGGTGGACAG 58.8
Reference SDHA GCCTTGGATCTCTTGATGGA 92 56.9 97 0.98
TTCTTGGCTCTTATGCGATG 55.9
Reference GAPDH TGAAGGGGTCATTGATGGCG 90 60.3 95 0.99
TCAACGGATTTGGCCGTATTGG 59.4
Target VDR ACTTGCATGAGGAGGAGCA 114 59 98 0.97
TGTTGGACAGGCGGTCTT 60
Target CYP27B1 CTGTATGAACTCGCTCGGCA 159 60 94 0.97
AGGGTACAGTCTCAGCACCT 59
Target CLD2 CAGCCCCTTGCAACTAGAGG 105 60.4 107 0.99
GCCCCTGGTTCTTCACACAT 60.3
Target ECAD TCAACCCAACCACGTACCAG 87 59.9 98 0.99
GGACATCAGCATCCGTCACT 59.8
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differences among groups (control, CE, and PLE). Reference gene expres-
sion was also shown to be stable using Best Keeper software.35
To minimize any technical, run-to-run variation between different sam-
ples for the comparison of gene expression, the maximum number of sam-
ples (in triplicate) were analyzed in each run.34 As not all samples could
be analyzed for 1 gene in the same run, control, and affected cases were
spread across 2 runs equally and inter-run calibrators were included. A
correction factor was then generated to control for inter-run differences.
Statistical Analysis
Relative expression software tool (REST), which has been previ-
ously validated,31 was used to analyze the qPCR results. This software
incorporates PCR efficiency correction and reference gene normaliza-
tion. It integrates a statistical analysis randomization algorithm to calcu-
late the statistical difference of variation between 2 groups and a
bootstrapping technique which provides 95% confidence interval for
expression ratios. The REST software uses a P(H1) test for the statisti-
cal analysis that involves a robust random sample reallocation to assess
for significance.36 qPCR data analysis was also performed using the
relative quantification method, delta delta CT (DDCT) method.37 The
relative quantification data generated were log2 transformed (Log2RQ)
for normalization.38 These Log2RQ values, IHC scores and signalment
details were assessed with a statistical program,q which was also used
for graphical representation of data.
Normality of data was tested by a D’argestine Pearson Omnibus nor-
mality test. Nonparametric analysis of ordinal categorical data was per-
formed with a Mann–Whitney test or for multiple subsets with a
Kruskal–Wallis. For continuous numerical data, a Spearman rank correla-
tion was performed. Several different factors were assessed for a relation-
ship to VDR and CYP27B1 expression; control versus dogs with CE,
type of disease (control, CE, and PLE), CIBDAI score, overall patholo-
gist morphological diagnosis category, WSAVA score, ECAD, and
CLD2 expression. P values and P(H1) values< 0.05 were considered sig-
nificant. For REST analysis, a CIBDAI cut off value of 9 was used as
this is consistent with severe clinical signs24 and the median WSAVA
score of 5 was used. Paired scatter plots and univariate analysis were per-
formed from all Log2RQ data before deciding on any additional analysis.
Images were captured with a BX41 light microscope with DP72
camera attachment and Cell^ D
VR
imaging software.r
For graphical representation of continuous data, to ensure all data
points could be appreciated, minimal randomized jitter was applied to
whole data sets.
Results
Vitamin D Receptor Expression in Non-Skeletal
Tissue
The 6 dogs collected for non-skeletal tissue expression
were 2 Staffordshire Bull terriers, a Mastiff, Border Collie,
Pitbull terrier, and Jack Russell terrier, with a median age of
4 years (range 2–8 years). Four of the 13 sampled organs
were overall moderate to strongly positive for the VDR:
duodenum, ileum, kidney, and skin (Fig 1). There was no
positive staining in the stomach or testicle samples.
Of the intestinal sections, duodenum had the highest aver-
age IHC OS of 1.67, while ileum was lower at 0.5 OS (Figs
1, 2). In the duodenum, there was strong nuclear labeling of
mucosal enterocytes, with weaker cytoplasmic labeling. In
both the duodenum and ileum the overall VDR immunolab-
elling score was higher in the crypt enterocytes compared to
the villous tips; goblet cells within the epithelial monolayer
were completely negative for VDR. There was minimal
labeling in the colon and typically only within the entero-
cyte nuclei.
In all renal samples, high numbers of cells stained with
moderate intensity (average IHC OS 2.33). Vitamin D
receptor labeling in the skin was of moderate intensity,
mainly concentrating within the hair bulb, outer root sheath,
and shaft (0.5 OS) and the non-keratinized layer of the epi-
dermis (stratum basale). Immunolabelling of the spleen was
weak to moderate (average IHC OS of 0.17). There were
several organs that labeled weakly and only within a low
number of cells, including lymph nodes, heart, liver, ovary,
and lung (Figs 1, 2).
Signalment and Pathological Scores of Control Dogs
and Dogs with Chronic Enteropathy
The 34 dogs with CE included 25 different breeds and 2
cross breed dogs. The 24 dogs without clinical signs of CE
included 10 different breeds and 4 cross breed dogs (Table
3). Median age was 5 years for both groups (range 2–17
years). Age and sex were not significantly different between
the populations, though there was a nonsignificantly higher
proportion of male dogs in the CE group.
The median CIBDAI of CE dogs was 9 (range 3–16) and
the duration of clinical signs before presentation was a
median of 7 weeks (range 4 weeks to 3 years). Inflammatory
changes were present in all dogs with CE and the median
WSAVA score was 5 (range 1–14). The WSAVA score was
significantly higher in dogs with CE compared to controls
(P5 0.0001). Of the 34 dogs with CE, 10 had a low serum
albumin and were classified as a PLE.
Of these, 1 control dog was excluded from the IHC analy-
sis because of lack of sufficient sample. One control dog
was removed from qPCR analysis because of low RNA
quality and finally, 2 CE dogs were removed because of
consistently high threshold cycle values indicating sample
degradation during the final stages of sample preparation.
Duodenal Vitamin D Receptor Expression in Control
Dogs and Dogs with Chronic Enteropathy
VDR mRNA expression was identified in the duodenum
of both control dogs and those with CE. REST analysis
identified no significant difference between controls and
dogs with CE or PLE. Mann–Whitney statistical testing
identified no significant difference in VDR qPCR expres-
sion (Log2RQ values) between control dogs and dogs with
CE, P5 0.87. There was also no significant difference
between these populations in protein expression (IHC OS),
P5 0.099 (Figs 3, 4). RNA expression of CYP27B1 was
low for both control dogs and those with CE. REST analysis
and Log2RQ value analysis of CYP27B1 identified no sig-
nificant differences in RNA expression, P5 0.22.
Duodenal Vitamin D Receptor Expression from Dogs
with Chronic Enteropathy with Increasing
Inflammation
REST analysis showed no significant difference in VDR
or CYP27B1 expression between dogs with mild
4 Cartwright et al
inflammation and dogs with moderate to marked inflamma-
tion. There was no significant difference in expression when
a high WSAVA score (ie> 5) was compared to a score of 2
or less and no difference in expression when a high CIBDAI
score (ie> 9) was compared to a score of <3.
Spearman rank correlation showed no association
between VDR RNA expression (Log2RQ), the WSAVA
score (r5 0.2288, P5 0.11) and the CIBDAI (r520.1488,
P5 0.39). There was also no correlation between the VDR
IHC OS and the WSAVA score (r5 0.2204, P5 0.099) and
Fig 1. Overall vitamin D receptor immunohistochemistry expression score in the 13 non-skeletal tissues and an isotype control. Heart (A), kid-
ney (B), liver (C), lymph node (D), lung (E), ovary (F), skin (G), spleen (H), testicle (I), stomach (J), duodenum (K), ileum (L) colon (M) nega-
tive control duodenum, as this organ was shown as it had the highest staining intensity (N). Scale Bar is equal to 200 lm.
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CIBDAI, (r5 0.05171, P5 0.7) (Fig 5). Spearman rank cor-
relation showed no association between CYP27B1 RNA
expression (Log2RQ), the WSAVA score (r5 0.2165,
P5 0.3) and the CIBDAI (r520.1538, P5 0.47).
Comparison of Duodenal Vitamin D Receptor
Expression and Related Proteins in Dogs with
Chronic Enteropathy
Spearman rank correlation showed no association
between VDR RNA expression (Log2RQ) and RNA expres-
sion of two of the tight junction components CLD2 and
ECAD. There was also no correlation between the
respective overall IHC scores for VDR, and RNA expres-
sion of CLD2 and ECAD.
Discussion
This study establishes which non-skeletal tissues express
VDR in the dog. The tissues expressing VDR at the highest
level; kidney, duodenum, and ileum were an expected find-
ing based on a previous study in dogs23 and the known
classical calcium homeostasis roles of these tissues. The
moderate expression within the skin has not previously been
reported in the dog. There were multiple tissues with weak
positive expression of VDR, with only the stomach and tes-
ticle being negative. The second major finding of this study
was that duodenal VDR expression, both RNA and protein,
did not decrease with inflammation. This contrasts with the
changes reported in both human and rodent colonic
inflammation.39,40
Our study is the first to establish that canine skin expresses
high levels of VDR, a finding that is similar to those observed
in other species.41 This finding is noteworthy, given the fact
that the dog does not produce significant levels of cutaneous
vitamin D from ultraviolet light.42,43 In cats, there is also a
lack of cutaneous vitamin D production, caused by increased
activity of the enzyme 7-dehydrocholesterol reductase,44 but
the cause is unknown in the dog. Active vitamin D
Fig 3. Vitamin D receptor (VDR) immunohistochemistry overall
score (left) and VDR Log2RQ value (right) for control and CE dogs.
Fig 2. Overall vitamin D receptor immunohistochemistry expression
score in the 13 non-skeletal tissues from 6 dogs.
Table 3. Breeds composing the two groups, chronic
enteropathy, and control dogs.
CE breeds Control Breeds
Greyhound Border Collie 3 3
Airedale Terrier Bull terrier
Alaskan Malamute Canadian Mastiff 3 2
Border Collie 3 3 Cross breed 3 4
Boxer Labrador
Cross breed 3 2 Pitbull 3 2
Cavachon Rottweiler
Cocker Spaniel Samoyed
English Springer Spaniel SBT 3 7
Flat Coat Retreiver Yorkshire Terrier
French Bulldog WHWT
German Short Haired Pointer
Golden Retriever
Gos D’Atura Catalan
Irish Setter
Japanese Akita
JRT 3 2
Labrador 3 3
Lakeland Terrier 3 2
Lhasa Apso
Lurcher
Maltese Terrier
Nova Scotia Duck Tolling
Pekinese
Rottweiler
WHWT 3 3
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metabolites stimulate differentiation and inhibit proliferation
of human keratinocytes via the VDR.45 The expression, par-
ticularly within the hair bulb, has also been documented in
people and in mouse models. VDR mouse knockout models
develop alopecia, indicating that the VDR is important for
follicular growth.41,46 It is intriguing to speculate whether
there are breed differences with regards to VDR receptors in
the skin; especially with reference to the hairless Chinese
Crested dog.
Weakly positive VDR expression in the lymph node and
spleen is consistent with findings in people1,41 and
mice.47,48 Specifically, VDR has been identified in activated
human inflammatory cells2 and 1,25(OH)2D has been
shown to inhibit T cell proliferation.49 VDR has also been
immunohistochemically identified in neoplastic canine mast
cells.50 Some of the positive cells in the lungs, lymph nodes,
spleen, and liver could be mast cells or other inflammatory
cells. There was only weak VDR expression in the colon in
healthy dogs, a finding which is different to people and
other species.39,51 In human ulcerative colitis and in mouse
models of colitis, VDR expression is negatively correlated
with colonic inflammation.
In contrast to findings in humans with IBD, which have
significantly decreased intestinal VDR expression,39,52 we
found no difference in VDR expression in the duodenum of
dogs with gastrointestinal inflammation. Assessments of
inflammation by several criteria and by multiple methods
showed no significant decline in VDR (Fig 4). There was
also no correlation identified with ECAD, a tight junction
element, which has been shown to decrease with ulcerative
colitis and Crohn’s disaese53,54 and IBD in dogs.28 Last,
there was no correlation with CLD2, another tight junctional
element that increases with intestinal inflammation in peo-
ple,55–57 and in dogs with CE.29
There are numerous studies which indicate a role for the
VDR in the protection against inflammation. For example,
VDR null mice develop more severe colitis, and clinical
signs can be attenuated by reconstitution of the intestinal
Fig 4. Duodenum of control dogs (A, C, E) and dogs with chronic enteropathy (B, D, F) illustrating immunolabelling of Vitamin D receptor.
Scale Bar is equal to 200, 100, and 50 lm, respectively.
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epithelial VDR.58 Vitamin D and the VDR have been shown
to be important regulators of the immune system in IBD.59
It has also been clearly demonstrated that serum vitamin D
is reduced in dogs with CE20 and is negatively correlated
with inflammation.22 In several cases of canine CE there is
a documented decrease in calcium21 and increased parathy-
roid hormone (PTH).20 The VDR and 1,25(OH)2D are both
required for calcium absorption, so in this species, despite
high expression of the VDR, there is evidence that calcium
becomes low enough to result in an increase in PTH,
because of lack of 1,25(OH)2D.
A functional local vitamin D synthesizing system has
been indicated as important for the prevention of IBD.60
The fact that the VDR is highly expressed in dogs regardless
of inflammation could indicate that a lack of the binding
substrate, 1,25(OH)2D is more important in the pathogenesis
of the inflammation than the receptor itself. This could be
caused by systemically low serum 25(OH)D, as has been
measured,20 or because of low local activity levels of
CYP27B1 or, finally, because of increased 1,25-dihydroxy-
vitamin D3 24-hydroxylase, (CYP24A1) levels, which nor-
mally reduce 1,25(OH)2D levels in a negative feed-back
manner. It is likely that low serum 25(OH)D occurs in CE
because of intestinal loss of Vitamin D and its metabolites,
which are bound to plasma vitamin D binding protein, as
previously suggested.61 It would therefore be plausible to
investigate the effects of supplementation of calcitriol
(1,25(OH)2D) in dogs with CE that have low serum
25(OH)D. This concept is further supported by previous
studies showing that 1,25(OH)2D or a vitamin D analogue,
TX527, ameliorated inflammation, and clinical signs in
spontaneous murine models of IBD.62,63 A protective effect
of 1,25(OH)2D has also been reported in mouse models of
hepatitis64 and there are several studies indicating improved
immune tolerance,65 decreased proinflammatory cyto-
kines66 and increased anti-inflammatory cytokine responses
with 1,25(OH)2D.
67,68
A lack of significant change in qPCR expression of
CYP27B1 would indicate that this is not an enzyme that
is affected in dogs with CE, as has been observed by
some studies of human IBD69 and intestinal neoplasia.70
This would further support a potential beneficial outcome
of the addition of calcitriol in the treatment of canine
CE, with less requirement to consider the hydroxylation
steps, as some authors have sought to do.71 The expres-
sion of CYP27B1, however, in this study was overall
very low.
Our study confirms the expression of VDR in a large
number of non-skeletal tissues in the dog. We also showed
that intestinal VDR expression does not decrease in the
presence of inflammation, in contrast to humans and
rodents. The mechanism for this difference is unknown, but
it could reflect a more profound effect of systemically low
serum 25(OH)D on the development of CE. One potential
clinical implication is consideration of 1,25(OH)2D or its
analogues to ameliorate clinical signs. In this species, as the
VDR is still expressed at high levels in the duodenum, there
is higher available binding potential for ligand, which is
more likely to translate to a beneficial effect. Alongside
this, as vitamin D concentrations are less affected by sun-
light in the dog, there are fewer external environmental fac-
tors to consider, which may increase the dog’s value as a
naturally occurring model of the interplay between vitamin
D and chronic inflammatory conditions.
Fig 5. Vitamin D receptor (VDR) immunohistochemistry overall
score and VDR Log2RQ value for dogs with chronic enteropathy
plotted against histological inflammation (World Small Animal Vet-
erinary Association score) (A and C) or severity of clinical signs
(canine inflammatory bowel disease activity index) (B and D).
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